Intravacc, EpiVax partner for COVID-19 vaccine

By The Science Advisory Board staff writers

June 2, 2020 -- Intravacc and EpiVax have entered a collaborative agreement to further develop a novel vaccine against COVID-19 based on Intravacc's proprietary outer membrane vesicle (OMV) technology platform.

Outer membrane vesicles (OMVs) are spherical particles with intrinsic adjuvating properties. Empty OMVs can be loaded with antigens of choice via genetic engineering.

The joint venture will combine Intravacc's immunogenic OMV delivery platform with synthetically produced COVID-19 epitopes designed and optimized by EpiVax's immunoinformatics tools that generate safe and effective T-cell responses against SARS-CoV-2.

Preclinical studies to select the best peptide candidates have already begun. Intravacc will utilize its in-house pilot-scale facility for good manufacturing practices production of the OMV-peptide vaccine for phase I clinical studies, which are expected to begin in fourth quarter 2020, according to the firm.

Codiak partners with Ragon Institue for SARS-CoV-2 vaccine platform
Codiak BioSciences has entered into a strategic collaboration with the Ragon Institute of Massachusetts General Hospital, the Massachusetts Institute...
Honeywell develops tech to expedite vaccines, therapies
Honeywell has released Fast Track Automation, a series of technologies for the life sciences industry. The system will allow vaccines, treatments, and...
MilliporeSigma, Baylor partnering on COVID-19 vaccine
MilliporeSigma and Baylor College of Medicine have announced they are working to advance a vaccine manufacturing platform to fight COVID-19. The partnership...
Sinovac receives $15M for COVID-19 vaccine
Biopharmaceutical company Sinovac Biotech announced that Advantech Capital and Vivo Capital invested $15 million in the firm's research and development...
IAVI, Merck partner on SARS-CoV-2 vaccine
Merck and IAVI, a nonprofit scientific research organization, announced that they are partnering to develop a recombinant vesicular stomatitis virus vaccine...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter